Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Adjuvant systemic therapy for operable breast cancer.

¹Scottish Cancer Trials Office (MRC), Medical School, University of Edinburgh, UK.

British Medical Bulletin

|April 1, 1991

Summary

Adjuvant systemic therapy improves outcomes for operable breast cancer patients with poor prognosis. Further research is needed to optimize treatment selection for good prognosis disease and monitor long-term side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Optogenetic Tractography for anatomo-functional characterization of cortico-subcortical neural circuits in non-human primates.

Scientific reports·2018

Same author

Urinary 17-Ketosteroids and their Fractions in Women with Breast Cancer Treated by Endocrine Surgery.

British journal of cancer·2011

Same author

The peripheral blood flow and rectal and skin temperatures in hypertension.

American heart journal·2010

Same author

The heart in rheumatic fever.

The Medical clinics of North America·2010

Same author

The effect of splanchnic resection on the peripheral blood flow and rectal and skin temperatures in hypertension.

American heart journal·2010

Same author

Peripheral blood flow, rectal and skin temperature in congestive heart failure; the effects of rapid digitalization in this state.

Archives of internal medicine (Chicago, Ill. : 1908)·2010

Area of Science:

Oncology
Medical treatment

Background:

Adjuvant systemic therapy is a key component in managing operable breast cancer.
Established benefits include delayed relapse and prolonged survival, particularly for high-risk patients.

Purpose of the Study:

To review the current role and future directions of adjuvant systemic therapy in operable breast cancer.
To highlight the need for improved prognostic indicators and long-term morbidity monitoring in treatment selection.

Main Methods:

Review of current adjuvant systemic therapy guidelines for premenopausal and postmenopausal breast cancer patients.
Discussion of the need for randomized trials evaluating new biological prognostic indicators.

Main Results:

CMF polychemotherapy (6 months) is recommended for premenopausal women.
Daily tamoxifen (2-5 years) is recommended for postmenopausal women.
Evidence for adjuvant therapy in good prognosis disease requires further evaluation.

Conclusions:

Adjuvant systemic therapy is crucial for operable breast cancer, especially for poor prognosis cases.
Future research should focus on biological indicators for personalized treatment selection in good prognosis disease.
Long-term monitoring for delayed morbidity is essential for patient well-being.

Related Experiment Videos